Talecris stock slips as demand for blood-plasma products wane

12/1/2009 | News & Observer (Raleigh, N.C.), The

Shares of Talecris, a maker of blood plasma-derived treatments for various immune disorders, dropped Monday by almost 20% since reaching a high in early November, amid concerns that the company won't be able to sustain its rising profit into the coming year. Analysts say the economic downturn could create an oversupply in blood-plasma products as more people donate.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA